Be the first to like.

Share

While informed by the statement issued by the organizing committee for the international summit, the consensus study committee had broad discretion to arrive at its own findings and conclusions. The report represents the official views of NAS and NAM.

 

More about the study | Info on public meetings | Answers to frequently asked questions

 

Read or download the full report

 

Download a report in brief PDF (a 4-page summary of the report’s key findings)

 

1-page summaries: 

 

Genome editing is a powerful new tool for making precise alterations to an organism’s genetic material. Recent scientific advances have made genome editing more efficient, precise, and flexible than ever before. These advances have spurred an explosion of interest from around the globe in the possible ways in which genome editing can improve human health. The speed at which these technologies are being developed and applied has led many policymakers and stakeholders to express concern about whether appropriate systems are in place to govern these technologies and how and when the public should be engaged in these decisions. In a new report from the National Academy of Sciences and National Academy of Medicine, an expert committee considers important questions about the human application of genome editing including: Balancing potential benefits with unintended risks, governing the use of genome editing, incorporating societal values into clinical applications and policy decisions, and respecting the inevitable differences across nations and cultures that will shape how and whether to use these new technologies. The committee sets forth criteria that must be met before permitting clinical trials of heritable germline editing, provides conclusions on the crucial need for public education and engagement, and presents 7 general principles for the governance of human genome editing. Download the report now to read the recommendations. // On Twitter:  #GeneEditStudy

Be the first to like.

Share
NASEM

Tags: , , , , , , , , , , , ,

Leave a Reply